BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
11/26/2024 9:16:40 AM | Browse: 269 | Download: 1113
Publication Name World Journal of Cardiology
Manuscript ID 100046
Country China
ISSN 1949-8462 (online)
Open Access This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Copyright © The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Cardiac & Cardiovascular Systems
Manuscript Type Letter to the Editor
Article Title Comparative breakthrough: Umbilical cord mesenchymal stem cells vs bone marrow mesenchymal stem cells in heart failure treatment
Manuscript Source Invited Manuscript
All Author List Peng Li
ORCID
Author(s) ORCID Number
Peng Li http://orcid.org/0000-0002-9153-2955
Funding Agency and Grant Number
Funding Agency Grant Number
National High Level Hospital Clinical Research Funding Project BJ-2023-206
Corresponding Author Peng Li, MD, Department of Geriatics, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, No. 1 Dongdan, Dahua Road, Dongcheng District, Beijing 100730, China. lipbenzi@126.com
Key Words Mesenchymal stem cells; Heart failure; Umbilical cord-derived mesenchymal stem cells; Bone marrow-derived mesenchymal stem cells; Left ventricular ejection fraction; 6-minute walking distance; Cardiac regeneration therapy
Core Tip This article provides a comparative analysis of umbilical cord-derived mesenchymal stem cells (UC-MSCs) and bone marrow-derived mesenchymal stem cells (BM-MSCs) for the treatment of heart failure. UC-MSCs significantly increase left ventricular ejection fraction and exhibit a favorable safety profile, positioning them as a promising alternative to BM-MSCs. Future research should focus on optimizing administration protocols and understanding the long-term benefits of UC-MSCs in cardiac therapy.
Publish Date 2024-11-26 09:16
Citation

Li P. Comparative breakthrough: Umbilical cord mesenchymal stem cells vs bone marrow mesenchymal stem cells in heart failure treatment. World J Cardiol 2024; 16(12): 776-780

URL https://www.wjgnet.com/1949-8462/full/v16/i12/776.htm
DOI https://dx.doi.org/10.4330/wjc.v16.i12.776
Full Article (PDF) WJC-16-776-with-cover.pdf